scholarly journals Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial

BMJ ◽  
2008 ◽  
Vol 337 (sep01 1) ◽  
pp. a1198-a1198 ◽  
Author(s):  
J. F Price ◽  
M. C Stewart ◽  
I. J Deary ◽  
G. D Murray ◽  
P. Sandercock ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Randomised Controlled Trial ◽  
Low Dose ◽  
Controlled Trial ◽  
Elderly Adults ◽  
Middle Aged ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Randomised Controlled

scholarly journals Trial of feasibility and acceptability of routine low-dose aspirin versusEarlyScreeningTest indicated aspirin for pre-eclampsia prevention (TESTstudy): a multicentre randomised controlled trial

BMJ Open ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. e022056 ◽  
Author(s):  
Fionnuala Mone ◽  
Cecilia Mulcahy ◽  
Peter McParland ◽  
Fionnuala Breathnach ◽  
Paul Downey ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Low Dose ◽  
Controlled Trial ◽  
Low Risk ◽  
Uterine Artery Doppler ◽  
Dose Aspirin ◽  
Nulliparous Women ◽  
Low Dose Aspirin ◽  
Randomised Controlled ◽  
Screening Result

ObjectiveEvaluate the feasibility and acceptability of routine aspirin in low-risk women, compared with screening-test indicated aspirin for the prevention of pre-eclampsia and fetal growth restriction.DesignMulticentre open-label feasibility randomised controlled trial.SettingTwo tertiary maternity hospitals in Dublin, Ireland.Participants546 low-risk nulliparous women completed the study.InterventionsWomen underwent computerised randomisation to: Group 1—routine aspirin 75 mg from 11 until 36 weeks; Group 2—no aspirin and; Group 3—aspirin based on the Fetal Medicine Foundation screening test.Primary and secondary outcome measures(1) Proportion agreeing to participate; (2) compliance with protocol; (3) proportion where first trimester uterine artery Doppler was obtainable and; (4) time taken to issue a screening result. Secondary outcomes included rates of pre-eclampsia and small-for-gestational-age fetuses.Results546 were included in the routine aspirin (n=179), no aspirin (n=183) and screen and treat (n=184) groups. 546 of 1054 were approached (51.8%) and enrolled. Average aspirin adherence was 90%. The uterine artery Doppler was obtained in 98.4% (181/184) and the average time to obtain a screening result was 7.6 (0–26) days. Of those taking aspirin, vaginal spotting was greater; n=29 (15.1%), non-aspirin n=28 (7.9%), OR 2.1 (95% CI 1.2 to 3.6). Postpartum haemorrhage >500 mL was also greater; aspirin n=26 (13.5%), no aspirin n=20 (5.6%), OR 2.6 (95% CI 1.4 to 4.8).ConclusionLow-risk nulliparous women are open to taking aspirin in pregnancy and had high levels of adherence. Aspirin use was associated with greater rates of vaginal bleeding. An appropriately powered randomised controlled trial is now required to address the efficacy and safety of universal low-dose aspirin in low-risk pregnancy compared with a screening approach.Trial registration numberISRCTN (15191778); Post-results.

scholarly journals Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol)

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e047949
Author(s):  
Bosede Bukola Afolabi ◽  
Ochuwa Adiketu Babah ◽  
Titilope Adenike Adeyemo ◽  
Oluwakemi Ololade Odukoya ◽  
Chinyere Veronica Ezeaka ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Intrauterine Growth Restriction ◽  
Low Dose ◽  
Perinatal Death ◽  
Controlled Trial ◽  
Intrauterine Growth ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Ethical Approval ◽  
Randomised Controlled

IntroductionPregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR). Previously, we found an abnormality in prostacyclin–thromboxane ratio in sickle cell pregnant women, a situation that is also found in non-sickle pregnancies with PE and unexplained IUGR. Low-dose aspirin (LDA) has been shown to reduce the incidence of PE and IUGR in high-risk women by reducing the vasoconstrictor thromboxane while sparing prostacyclin, in effect ‘correcting’ the ratio. It has been found to be safe for use in pregnancy but has not been tested in sickle cell pregnancy. We hypothesise that LDA will reduce the incidence of IUGR and PE in pregnant haemoglobin SS (HbSS) and haemoglobin SC (HbSC) women.Methods and analysisThis is a multisite, double blind, randomised controlled trial, comparing a daily dose of 100 mg aspirin to placebo, from 12 to 16 weeks’ gestation until 36 weeks, in Lagos state, Nigeria. Four hundred and seventy-six eligible pregnant HbSS and HbSC women will be recruited consecutively, randomly assigned to either group and followed from recruitment until delivery. The primary outcome will be the incidence of birth weight below 10th centile for gestational age on INTERGROWTH 21 birth weight charts, or incidence of miscarriage or perinatal death. Secondary outcomes will include PE, maternal death, preterm delivery, perinatal death, number of crises, need for blood transfusion and complications such as infections and placental abruption. Analysis will be by intention to treat and the main treatment effects will be quantified by relative risk with 95% CI, at a 5% significance level.Ethical approvalEthical approval has been granted by the Health Research and Ethics committees of the recruiting hospitals and the National Health Research and Ethics Committee. Study findings will be presented at conferences and published appropriately.Trail registration numberPACTR202001787519553; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document